Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

Status Withdrawn

Clinical Trial Summary

The purpose of the study is to investigate the safety and efficacy of oral vancomycin in patients with recurrent Primary Sclerosing Cholangitis (PSC) after liver transplantation. The primary endpoint is looking at the effect of the drug on liver function tests, an important surrogate of PSC disease activity at 12 weeks on treatment. Secondary endpoints include a decrease in liver function tests at 1 year, changes in bilirubin and adverse events. Effective treatment at the onset of PSC recurrence may lead to decreases in disease progression, recurrent liver failure, and repeat liver transplantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cholangitis
Cholangitis, Sclerosing
Post- Orthotopic Liver Transplantation
Primary Sclerosing Cholangitis

Clinical Trial Details

NCT number	NCT03046901
Study type	Interventional
Source	Ochsner Health System
Contact
Status	Withdrawn
Phase	N/A
Start date	December 7, 2016
Completion date	February 25, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02239211` - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis	Phase 2
Withdrawn	`NCT03216876` - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis	Phase 1
Recruiting	`NCT02605213` - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients	Phase 4
Recruiting	`NCT01688024` - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis	Phase 2
Completed	`NCT03041662` - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed	`NCT05866809` - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis	Phase 2
Recruiting	`NCT05618145` - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting	`NCT02446665` - Disease Status in Primary Sclerosing Cholangitis by Elastography	N/A
Completed	`NCT02247934` - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)	N/A
Completed	`NCT01088607` - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis	Phase 1
Terminated	`NCT01142323` - Pilot Study of Fenofibrate for PSC	Phase 1/Phase 2
Terminated	`NCT04060147` - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis	Phase 1
Recruiting	`NCT04133792` - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)	Phase 3
Active, not recruiting	`NCT04595825` - CM-101 in PSC Patients -The SPRING Study	Phase 2
Recruiting	`NCT03183570` - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT	Early Phase 1
Completed	`NCT02943460` - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis	Phase 2
Completed	`NCT00951327` - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP)	N/A
Completed	`NCT04024813` - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC	Phase 2
Recruiting	`NCT05912387` - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study	Early Phase 1
Completed	`NCT02884557` - NKT Role in the Regulation of the Inflammatory Bowel Disease	N/A